Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2005

Conditions
Head and Neck Cancer
Interventions
DRUG

imatinib mesylate

Trial Locations (15)

46601

CCOP - Northern Indiana CR Consortium, South Bend

49085

Lakeland Medical Center - St. Joseph, Saint Joseph

60153

Loyola University Medical Center, Maywood

60201

Evanston Northwestern Health Care - Evanston Hospital, Evanston

60426

Ingalls Memorial Hospital, Harvey

60525

LaGrange Memorial Hospital, LaGrange

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

63110

Siteman Cancer Center, St Louis

60637-1470

University of Chicago Cancer Research Center, Chicago

46885-5099

Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne

53792-6164

University of Wisconsin Comprehensive Cancer Center, Madison

L8V 5C2

Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00045669 - Imatinib Mesylate in Treating Patients With Salivary Gland Cancer | Biotech Hunter | Biotech Hunter